<DOC>
	<DOC>NCT00223964</DOC>
	<brief_summary>This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria.</brief_summary>
	<brief_title>Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male or female pediatric endstage renal disease (ESRD) patients. Predetermined TSAT and serum ferritin levels Receiving chronic hemodialysis therapy with an identified need for repletion iron therapy. Receiving a stable epoetin (EPO) dosing regimen. Receipt of any form of iron supplements during the 4 weeks prior to the first Ferrlecit® dosing. Blood transfusion. Hypersensitivity to Ferrlecit®. Significant inflammatory conditions.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Iron Deficiency</keyword>
	<keyword>Anemia in Pediatric Hemodialysis</keyword>
</DOC>